Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on December 8th, 2023%
The developer of an experimental immunotherapy delivering nanoscale payloads to treat pancreatic cancer says the treatment received fast-track status from the Food and Drug Administration. . . . → Read More: Nanotech Pancreatic Cancer Immunotherapy Gains FDA Fast Track
By Alan, on December 6th, 2023%
A developer of treatments for cancer and autoimmune disorders from stem cells says FDA cleared its request to start a clinical trial of its therapy for systemic lupus erythematosus. . . . → Read More: Trial Okayed for Gene-Edited Stem Cell Lupus Treatment
By Alan, on December 4th, 2023%
A company developing DNA into a feasible method for large-scale data storage unveiled a credit card-sized device using DNA for off-line data storage. . . . → Read More: DNA Data Company Creates Portable Storage Media
By Alan, on December 1st, 2023%
A collaboration between biotechnology and dairy products businesses seeks to identify peptides in milk to form into dietary supplements for people with mood disorders. . . . → Read More: Partnership to Discover Mental Health Peptides in Milk
By Alan, on November 30th, 2023%
A developer of medical monitoring systems with data from wearable devices will soon start asking individuals with epilepsy to offer data for an algorithm that predicts seizures. . . . → Read More: Study to Provide Real World Data for A.I. Seizure Forecasts
By Alan, on November 28th, 2023%
A developer of messenger RNA therapies for respiratory and rare diseases says it received clearance to begin a clinical trial in the U.K. for an inhaled treatment for viral lung conditions. . . . → Read More: Trial Set to Test Inhaled mRNA for Viral Infections
By Alan, on November 27th, 2023%
A vaccine delivered with a patch device is shown in a clinical trial to generate neutralizing antibodies against measles and rubella similar to conventional injections. . . . → Read More: Vaccine Patch Shown Safe, Produces Measles/Rubella Antibodies
By Alan, on November 24th, 2023%
Researchers from university labs in the U.K. are developing models of brain cell interactions using a company’s synthetic human cells derived from stem cells. . . . → Read More: Academic, Industry Labs to Build Brain Cell Models
By Alan, on November 22nd, 2023%
A company producing tissue samples in the lab, for drug discovery and preclinical research with robotics and artificial intelligence, raised $38 million in seed funding. . . . → Read More: Lab-Grown Tissue Company Gains $38M in Seed Funds
By Alan, on November 21st, 2023%
A challenge competition with a $50 million purse seeks new strategies to attack the global substance abuse epidemic, including personalized diagnostics and treatments. . . . → Read More: Challenge Seeks Precise Addiction Strategies, Biomarkers, Treatments
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|